Research Index
SHLP2 (Small Humanin-Like Peptide 2) Research Index
PSI surfaces 50 peer-reviewed studies on SHLP2 (Small Humanin-Like Peptide 2), prioritized by evidence strength: human clinical research first, then animal studies. The full historical archive is linked below on PubMed.
50 studies
Combined antiretroviral therapy with low- or normal-protein, high-calorie diets appears to induce significant deleterious electrocardiographic changes in a rodent model.
Chege BM, Mwangi PW, Githinji CG et al.
Braz J Med Biol Res·2026·Animal·PubMed →
Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry.
Uçaktürk E, Nemutlu E
J Pharm Biomed Anal·2026·Animal·GH Activity·PubMed →
Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity.
Ellis RJ, Vaida F, Hu K et al.
J Infect Dis·2025·Human·GH Activity·PubMed →
Carpal Tunnel Syndrome Attributed to Medication Use: A Pharmacovigilance Study.
Mihalache A, Volfson E, Huang R et al.
Cureus·2025·Animal·PubMed →
Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.
Russo SC, Ockene MW, Arpante AK et al.
AIDS·2024·Human·GH Activity·PubMed →
Dietary regimens appear to possess significant effects on the development of combined antiretroviral therapy (cART)-associated metabolic syndrome.
Chege BM, Mwangi PW, Githinji CG et al.
PLoS One·2024·Animal·Metabolic Syndrome, Weight Loss·PubMed →
Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples.
Thomas A, Walpurgis K, Thevis M
J Mass Spectrom·2024·Animal·GH Activity·PubMed →
Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial.
Rahman F, McLaughlin T, Mesquita P et al.
J Clin Transl Sci·2023·Human·PubMed →
Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples.
Cristea CD, Radu M, Toboc A et al.
Anal Biochem·2023·Animal·PubMed →
Proteomic Analysis of Hepatic Fibrosis in Human Immunodeficiency Virus-Associated Nonalcoholic Fatty Liver Disease Demonstrates Up-regulation of Immune Response and Tissue Repair Pathways.
Fourman LT, Stanley TL, Ockene MW et al.
J Infect Dis·2023·Animal·Liver Fat (MASLD), Liver Protection·PubMed →
Approach to the Patient With Lipodystrophy.
Fourman LT, Grinspoon SK
J Clin Endocrinol Metab·2022·Human·Glycemic Control, Weight Loss·PubMed →
Probing for peptidic drugs (2-10 kDa) in doping control blood samples.
Thomas A, Thilmany S, Hofmann A et al.
Anal Sci Adv·2022·Animal·PubMed →
An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.
Coppieters G, Deventer K, Polet M et al.
J Pharm Biomed Anal·2022·Animal·GH Activity·PubMed →
Growth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways in Individuals with HIV-infection and Nonalcoholic Fatty Liver Disease.
Stanley TL, Fourman LT, Wong LP et al.
Clin Infect Dis·2021·Human·GH Activity, Liver Fat (MASLD)·PubMed →
Relationship of IGF-1 and IGF-Binding Proteins to Disease Severity and Glycemia in Nonalcoholic Fatty Liver Disease.
Stanley TL, Fourman LT, Zheng I et al.
J Clin Endocrinol Metab·2021·Human·Glycemic Control, GH Activity, Liver Fat (MASLD)·PubMed →
Clinical Predictors of Liver Fibrosis Presence and Progression in Human Immunodeficiency Virus-Associated Nonalcoholic Fatty Liver Disease.
Fourman LT, Stanley TL, Zheng I et al.
Clin Infect Dis·2021·Human·PubMed →
Advances in the detection of growth hormone releasing hormone synthetic analogs.
Memdouh S, Gavrilović I, Ng K et al.
Drug Test Anal·2021·Animal·GH Activity·PubMed →
Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach.
Fourman LT, Stanley TL, Billingsley JM et al.
Sci Rep·2021·Animal·GH Activity, Liver Fat (MASLD)·PubMed →
Tesamorelin improves fat quality independent of changes in fat quantity.
Lake JE, La K, Erlandson KM et al.
AIDS·2021·Animal·GH Activity·PubMed →
Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD.
Fourman LT, Billingsley JM, Agyapong G et al.
JCI Insight·2020·Human·GH Activity, Liver Protection, Liver Fat (MASLD)·PubMed →
Comparison of magnetic bead surface functionalities for the immunopurification of growth hormone-releasing hormones prior to liquid chromatography-high resolution mass spectrometry.
Pont L, Alechaga É, Terrero A et al.
J Chromatogr A·2020·Animal·GH Activity·PubMed →
Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.
Stanley TL, Fourman LT, Feldpausch MN et al.
Lancet HIV·2019·Human·PubMed →
The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.
Adrian S, Scherzinger A, Sanyal A et al.
J Frailty Aging·2019·Human·GH Activity, Muscle Recovery·PubMed →
Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation.
Braun LR, Feldpausch MN, Czerwonka N et al.
Growth Horm IGF Res·2017·Human·Liver Fat (MASLD), GH Activity, Anti-Inflammatory·PubMed →
Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial.
Clemmons DR, Miller S, Mamputu JC
PLoS One·2017·Human·Glycemic Control, GH Activity·PubMed →
Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat.
Mangili A, Falutz J, Mamputu JC et al.
PLoS One·2015·Human·GH Activity·PubMed →
Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects.
González-Sales M, Barrière O, Tremblay PO et al.
J Pharmacokinet Pharmacodyn·2015·Human·GH Activity·PubMed →
Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects.
González-Sales M, Barrière O, Tremblay PO et al.
Clin Pharmacokinet·2015·Human·Weight Loss, GH Activity·PubMed →
Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.
Stanley TL, Feldpausch MN, Oh J et al.
JAMA·2014·Human·Liver Fat (MASLD), GH Activity, Liver Protection·PubMed →
The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.
Makimura H, Murphy CA, Feldpausch MN et al.
J Clin Endocrinol Metab·2014·Human·GH Activity, Weight Loss·PubMed →
Growth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy aging.
Friedman SD, Baker LD, Borson S et al.
JAMA Neurol·2013·Human·Longevity, GH Activity·PubMed →
Recombinant human growth hormone and rosiglitazone for abdominal fat accumulation in HIV-infected patients with insulin resistance: a randomized, double-blind, placebo-controlled, factorial trial.
Glesby MJ, Albu J, Chiu YL et al.
PLoS One·2013·Human·Glycemic Control, GH Activity·PubMed →
Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial.
Makimura H, Feldpausch MN, Rope AM et al.
J Clin Endocrinol Metab·2012·Human·Cardiovascular Risk, GH Activity·PubMed →
Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial.
Baker LD, Barsness SM, Borson S et al.
Arch Neurol·2012·Human·PubMed →
Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.
Stanley TL, Falutz J, Marsolais C et al.
Clin Infect Dis·2012·Human·GH Activity·PubMed →
Relationship of adiponectin to endogenous GH pulse secretion parameters in response to stimulation with a growth hormone releasing factor.
Makimura H, Stanley TL, Chen CY et al.
Growth Horm IGF Res·2011·Human·GH Activity, Weight Loss·PubMed →
Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction.
Stanley TL, Falutz J, Mamputu JC et al.
AIDS·2011·Human·GH Activity, Anti-Inflammatory·PubMed →
Growth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled trials.
Sivakumar T, Mechanic O, Fehmie DA et al.
HIV Med·2011·Human·GH Activity, Metabolic Syndrome, Muscle Recovery·PubMed →
Tesamorelin for the treatment of excess abdominal fat in HIV-1-infected patients with lipodystrophy.
Mateo MG, Gutiérrez MDM, Domingo P
Expert Rev Endocrinol Metab·2011·Human·PubMed →
Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.
Falutz J, Mamputu JC, Potvin D et al.
J Clin Endocrinol Metab·2010·Human·GH Activity·PubMed →
Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.
Falutz J, Potvin D, Mamputu JC et al.
J Acquir Immune Defic Syndr·2010·Human·GH Activity·PubMed →
Therapeutic trial of growth hormone releasing factor in HIV patients.
Winslow DL
AIDS Alert·2008·Human·GH Activity·PubMed →
Tesamorelin for fat accumulation. 52-week effects and safety of tesamorelin (growth hormone releasing factor) in HIV patients with fat accumulation.
Berger D
Posit Aware·2008·Human·GH Activity·PubMed →
Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.
Falutz J, Allas S, Mamputu JC et al.
AIDS·2008·Human·GH Activity·PubMed →
Approach to the human immunodeficiency virus-infected patient with lipodystrophy.
Brown TT
J Clin Endocrinol Metab·2008·Human·Cardiovascular Risk, GH Activity, Glycemic Control·PubMed →
Effects of growth hormone-releasing factor in HIV-infected patients.
Malgarini RB, Pimpinella G
N Engl J Med·2008·Human·PubMed →
Manipulation of the growth hormone axis in patients with HIV infection.
Blackman MR
N Engl J Med·2007·Human·PubMed →
Metabolic effects of a growth hormone-releasing factor in patients with HIV.
Falutz J, Allas S, Blot K et al.
N Engl J Med·2007·Human·Cardiovascular Risk, GH Activity·PubMed →
Side effects and complications. Tesamorelin--results from Phase III.
TreatmentUpdate·2007·Human·GH Activity·PubMed →
A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation.
Falutz J, Allas S, Kotler D et al.
AIDS·2005·Human·GH Activity·PubMed →